Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

被引:0
作者
Kathrin Gennen
Lukas Käsmann
Julian Taugner
Chukwuka Eze
Monika Karin
Olarn Roengvoraphoj
Jens Neumann
Amanda Tufman
Michael Orth
Simone Reu
Claus Belka
Farkhad Manapov
机构
[1] University Hospital,Department of Radiation Oncology
[2] LMU Munich,Department of Pathology
[3] Comprehensive Pneumology Center Munich (CPC-M),undefined
[4] Member of the German Center for Lung Research (DZL),undefined
[5] German Cancer Consortium (DKTK),undefined
[6] Institute of Pathology,undefined
[7] Faculty of Medicine,undefined
[8] Department of Internal Medicine V,undefined
[9] Thoracic Oncology Centre Munich,undefined
[10] Division of Respiratory Medicine and Thoracic Oncology,undefined
[11] University Hospital Wuerzburg,undefined
来源
Radiation Oncology | / 15卷
关键词
TILs; PDL1; Chemoradiotherapy; Prognostic factors; Checkpoint inhibition;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 370 条
[1]  
Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
[2]  
Miller KD(2016)The International Association for the Study of Lung Cancer lung Cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer J Thorac Oncol 11 300-311
[3]  
Jemal A(2018)Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer Strahlenther Onkol 194 79-90
[4]  
Nicholson AG(2017)Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 28 iv1-iv21
[5]  
Chansky K(2017)Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy Radiat Oncol 12 122-821
[6]  
Crowley J(2018)NCCN guidelines insights: non–small cell lung cancer, version 5.2018 J Natl Compr Cancer Netw 16 807-e185
[7]  
Beyruti R(2017)Treatment variation of sequential versus concurrent Chemoradiotherapy in stage III non-small cell lung Cancer patients in the Netherlands and Belgium Clin Oncol 29 e177-1929
[8]  
Kubota K(2017)Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer N Engl J Med 377 1919-2350
[9]  
Turrisi A(2018)Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 379 2342-54
[10]  
Eberhardt WE(2019)State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours—a German radiation oncology survey Eur J Cancer 108 50-2109